 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
New Approach Could Lower Antibiotic Requirements By Fifty Times
Los Angeles CA (SPX) Jan 30, 2007 Steven Hagens, previously at the University of Vienna, told Chemistry and Industry, the magazine of the SCI, that certain bacteriophages, a type of virus that infects bacteria, can boost the effectiveness of antibiotics gentamicin, gramacidin or tetracycline. It is the phages' ability to channel through bacterial cell membranes that boosts antibiotic effectiveness. 'Pseudomonas bacteria for example are particularly multi-resistant to antibiotics because they have efflux pump mechanisms that enable them to throw out antibiotics. A pore in the cell wall would obviously cancel the efflux effect,' Hagens explains. Pseudomonas bacteria cause pneumonia and are a common cause of hospital-acquired infections. Experiments in mice revealed that 75% of those infected with a lethal dose of Pseudomonas survived if the antibiotic gentamicin was administered in the presence of bacteriophages. None survived without the phages (Microb. Drug Resist., 2006, 12 (3), 164). The bacteriophage approach would also be particularly useful for treating cases of food poisoning, because the lower doses of antibiotic needed would not disrupt the friendly bacteria in the gut - a big problem with conventional antibiotic treatments. 'The prospect of using such treatments to prolong the life of existing agents and delay the onset of widespread resistance is to be welcomed,' said Jim Spencer a lecturer in microbial pathogenesis at the University of Bristol. The overuse of antibiotics since the 1940s had slowly created a host of infections that are resistant to antibiotics. MRSA (Methicillin-resistant Staphylococcus aureus) for example is rapidly spreading through hospitals, affecting more than 8,000 people in the UK every year. MRSA infection can lead to septic shock and death. Related Links Society of Chemical Industry Hospital and Medical News at InternDaily.com Hospital and Medical News at InternDaily.com
Expert Panel Wary Of New Depression Device
Washington (UPI) Jan 26, 2007An expert panel took a dim view of a new brain stimulation device for depression Friday, apparently damaging the chances that Food and Drug Administration will approve the product. Advisors said they were skeptical that the device, called NeuroStar, is effective in depressed patients, or that it poses any advantage over placebo. The device resembles a dentist's chair with metal electrodes attached to a nearby console. |
|
|
| The content herein, unless otherwise known to be public domain, are Copyright Space.TV Corporation. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space.TV Corp on any Web page published or hosted by Space.TV Corp. Privacy Statement |
